کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
10211912 1669923 2018 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی بیهوشی و پزشکی درد
پیش نمایش صفحه اول مقاله
SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q
چکیده انگلیسی
Myelodysplastic syndrome (MDS) with deletion 5q [del(5q)] is a distinct clinical and pathologic disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Lenalidomide resistance, including primary resistance, occurs by clonal evolution, which is frequently attributable to the presence of somatic mutations in the DNA-binding domain of the TP53 gene. The treatment options after development of resistance to lenalidomide are limited and consist of hypomethylating agents, clinical trials, and allogeneic hematopoietic stem cell transplantation. We discuss evidence-based strategies to devise a treatment algorithm for patients with MDS with del(5q).
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Lymphoma Myeloma and Leukemia - Volume 18, Issue 10, October 2018, Pages 629-635
نویسندگان
, , ,